Physician profile

Isha Lopez

Dermatology · Pasadena, TX

NPI 1922393131

$22,260.84

in general payments reported to CMS, 2019-2025

44 companies · $4,680 in 2025

The $4,680 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$12,727.56
Education$194.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $3,237.23 2019-2025
Janssen Biotech, INC. $2,568.73 2019-2025 Tremfya
Novartis Pharmaceuticals Corporation $2,089.13 2019-2025
Regeneron Healthcare Solutions, INC. $1,651.19 2019-2025 Dupixent
Leo Pharma INC. $1,384.41 2019-2025 Adbry, Anzupgo
Genzyme Corporation $1,355.87 2019-2025
Lilly USA, LLC $1,153.80 2019-2025 Taltz, Ebglyss
Sun Pharmaceutical Industries INC. $1,035.12 2019-2025 Absorica Ld, Winlevi, Blu-U
Pfizer INC. $813.19 2019-2025
Incyte Corporation $812.60 2021-2025 Opzelura
Amgen INC. $793.70 2019-2025 Otezla, Otezla
Arcutis Biotherapeutics, INC. $623.57 2023-2025 Zoryve
Ucb, INC. $615.43 2020-2025 Bimzelx, Cimzia
Dermavant Sciences, INC. $476.03 2022-2024 Vtama
Mayne Pharma Commercial LLC $401.84 2019-2025
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Galderma Laboratories, L.P. $398.87 2019-2025 Aklief, Oracea, Nemluvio
Ortho Dermatologics, A Division of Bausch Health US, LLC $362.04 2019-2025 Jublia, Cabtreo, Arazlo
E.R. Squibb & Sons, L.L.C. $314.80 2022-2025 Sotyktu
Paratek Pharmaceuticals, INC. $305.91 2021-2025 Nuzyra
Organogenesis INC. $217.23 2021-2024 Puraply
Epi Health, LLC $206.44 2019-2022
Hill Dermaceuticals, INC. $188.74 2020-2024 Tolak
Almirall LLC $172.47 2020-2025 Seysara, Klisyri
Organon LLC $157.98 2025 Vtama
Mallinckrodt Hospital Products INC. $133.35 2024-2025 Acthar
Glaxosmithkline, LLC. $111.53 2019-2023 Trelegy Ellipta
Dermira, INC. $102.38 2019-2021
Journey Medical Corporation $85.44 2020-2021
Medimetriks Pharmaceuticals, INC. $63.95 2020-2021
Celgene Corporation $62.61 2019
Vyne Pharmaceuticals INC. $50.93 2020
Biofrontera INC. $42.98 2019-2021
Genentech USA, INC. $39.72 2020-2022
Helsinn Therapeutics (U.S.), INC. $32.53 2023-2025 Valchlor
Springworks Therapeutics, INC. $28.04 2025 Gomekli
Nabriva Therapeutics, Plc $27.22 2020-2022
Sebela Pharmaceuticals INC. $24.00 2020
Teva Pharmaceuticals USA, INC. $19.85 2024 Simlandi
Tempus Ai, INC $19.79 2024 Merlin Test
Boehringer Ingelheim Pharmaceuticals, INC. $19.19 2024 Spevigo
Verrica Pharmaceuticals INC. $17.61 2025 Ycanth
Elekta, INC. $16.71 2025 Flexitron Hdr
Melinta Therapeutics, LLC $15.35 2019
Merck Sharp & Dohme LLC $11.34 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Isha Lopez

$22,260.84

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $4,680 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).

https://glasscript.com/doctor/588890/isha-lopez

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.